Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,415.80 -1.88 -0.01%
TOPIX 1,167.52 0.97 0.08%
HANG SENG 22,784.20 88.19 0.39%

Agios Pharmaceuticals Appoints Paul J. Clancy to Its Board of Directors



  Agios Pharmaceuticals Appoints Paul J. Clancy to Its Board of Directors

Business Wire

CAMBRIDGE, Mass. -- September 26, 2013

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), today announced the addition of
Paul J. Clancy, executive vice president and chief financial officer at Biogen
Idec, to the company’s board of directors.

“As the CFO of a fully integrated, large cap biotechnology company, Paul
brings invaluable experience to Agios following our successful IPO,” said
David Schenkein, M.D., chief executive officer at Agios. “We expect that his
unique perspective and relevant industry experience will be immediately
beneficial to our team, and we believe his insights as an independent director
will be particularly valuable as we continue to mature as a company.”

Mr. Clancy has more than 20 years of experience in financial management and
strategic business planning. Mr. Clancy has served as the executive vice
president and chief financial officer at Biogen Idec since August 2007. He
also served as senior vice president of finance, with responsibilities for
leading the treasury, tax, investor relations and business planning groups.
Prior to the merger of Biogen and Idec, Mr. Clancy was the vice president of
portfolio management at Biogen Inc. He joined the company in 2001 as vice
president of U.S. marketing. Before Biogen Inc., Mr. Clancy spent 13 years at
PepsiCo, serving in a variety of financial and general management positions,
including vice president and general manager of their Great West Business
Unit. Mr. Clancy has an MBA from Columbia Business School in New York City and
received his B.S. in business administration from Babson College in Wellesley,
Mass.

“Agios is seeking to build a truly differentiated company focused on promising
research in cellular metabolism with potential to transform the lives of
patients,” said Mr. Clancy. “I am looking forward to working with David and
the rest of the board and management team as they continue in their efforts to
grow and advance their programs in cancer metabolism and inborn errors of
metabolism.”

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to
treat cancer and rare metabolic genetic diseases (known as inborn errors of
metabolism or IEMs) through scientific leadership in the field of cellular
metabolism. In addition to an active research and discovery pipeline across
both therapeutic areas, Agios has multiple first-in-class lead product
candidates in cancer metabolism and IEMs in clinical and preclinical
development. All Agios programs focus on genetically identified patient
populations leveraging our knowledge of metabolism, biology and genomics. For
more information, please visit our website at www.agios.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the expected benefits of Mr. Clancy’s service on the Board of
Directors of Agios and the Company’s plans for growth and advancement of its
programs. The words “believe,” “expect” “could,” “should,” “will,” “may” and
similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words.
Such statements are subject to important risks and uncertainties that may
cause actual events or results to differ materially from Agios’ current
expectations and beliefs, including the risks described under the caption
“Risk Factors” in Agios’ Quarterly Report on Form 10-Q for the quarter ended
June 30, 2013 which is on file with the Securities and Exchange Commission
(SEC), and other filings that Agios may make with the SEC in the future. Any
forward-looking statements contained in this press release speak only as of
the date hereof, and Agios expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:

For Agios Pharmaceuticals, Inc.
Media:
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Glenn Goddard
investors@agios.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement